This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Disease models			
Mouse models of human CC chemokine receptor 9 (CCR9; CDw199)-expressing colorectal cancer	<p>Mouse models based on CCR9-expressing human colorectal cancer cell lines could help identify new therapies to treat the disease. In colorectal cancer tumors from patients, CCR9 levels were upregulated in primary tumors and downregulated in metastatic tumors. In mice, cell lines derived from the CCR9-expressing primary colorectal cancer tumors produced a larger number of gastrointestinal tumors than cell lines derived from the metastatic tumors. In mice receiving the CCR9-expressing cells, small hairpin RNA against <i>CCR9</i> decreased tumor formation in the gastrointestinal tract but also increased tumor formation outside of it compared with scrambled control shRNA. Ongoing work includes using multiple CCR9-expressing colorectal cancer cell lines in xenograft mouse models to identify inhibitors of colorectal cancer metastasis.</p> <p>SciBX 5(32); doi:10.1038/scibx.2012.852 Published online Aug. 16, 2012</p>	Patent application filed covering the CCR9-expressing colorectal cancer cell lines; available for licensing	<p>Chen, H.J. <i>et al. J. Clin. Invest.</i>; published online Aug. 6, 2012; doi:10.1172/JCI62110 Contact: Steven Lipkin, Weill Cornell Medical College, New York, N.Y. e-mail: stl2012@med.cornell.edu</p>